Your browser doesn't support javascript.
loading
Smart-watch-programmed green-light-operated percutaneous control of therapeutic transgenes.
Mansouri, Maysam; Hussherr, Marie-Didiée; Strittmatter, Tobias; Buchmann, Peter; Xue, Shuai; Camenisch, Gieri; Fussenegger, Martin.
Afiliação
  • Mansouri M; Department of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland.
  • Hussherr MD; Department of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland.
  • Strittmatter T; Department of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland.
  • Buchmann P; Department of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland.
  • Xue S; Department of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland.
  • Camenisch G; Department of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland.
  • Fussenegger M; Department of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland. fussenegger@bsse.ethz.ch.
Nat Commun ; 12(1): 3388, 2021 06 07.
Article em En | MEDLINE | ID: mdl-34099676
Wearable smart electronic devices, such as smart watches, are generally equipped with green-light-emitting diodes, which are used for photoplethysmography to monitor a panoply of physical health parameters. Here, we present a traceless, green-light-operated, smart-watch-controlled mammalian gene switch (Glow Control), composed of an engineered membrane-tethered green-light-sensitive cobalamin-binding domain of Thermus thermophilus (TtCBD) CarH protein in combination with a synthetic cytosolic TtCBD-transactivator fusion protein, which manage translocation of TtCBD-transactivator into the nucleus to trigger expression of transgenes upon illumination. We show that Apple-Watch-programmed percutaneous remote control of implanted Glow-controlled engineered human cells can effectively treat experimental type-2 diabetes by producing and releasing human glucagon-like peptide-1 on demand. Directly interfacing wearable smart electronic devices with therapeutic gene expression will advance next-generation personalized therapies by linking biopharmaceutical interventions to the internet of things.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Proteínas de Bactérias / Transativadores / Diabetes Mellitus Tipo 2 / Peptídeo 1 Semelhante ao Glucagon / Optogenética Limite: Animals / Female / Humans / Male Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Proteínas de Bactérias / Transativadores / Diabetes Mellitus Tipo 2 / Peptídeo 1 Semelhante ao Glucagon / Optogenética Limite: Animals / Female / Humans / Male Idioma: En Ano de publicação: 2021 Tipo de documento: Article